Machine Learning

Clene Inc. heads to an investor conference with powerful new ALS data. But with a limited cash runway, the real test is securing market confidence.

PTC launches its Arena AI Engine to automate compliance and document review, offering a strategic advantage for complex defense and aerospace supply chains.

A home remodeler is a top IT workplace. The defense sector must learn from its model for talent development, which holds strategic national security lessons.

A.D.A.M. Innovations just launched ALUNAÉ, the world's first AI genomic-based skincare. Is this the future of beauty or a step too far?

Century Therapeutics adds M&A and investment heavyweights to its board, a strategic move to navigate the clinical gauntlet with its iPSC-derived diabetes cure.

A top FinTech firm's new product chief reveals a strategic roadmap for taming complexity that the defense and space sectors cannot afford to ignore.

Celldex is launching a pivotal Phase 3 trial for a drug that could be the first advanced therapy for two debilitating and untreated chronic hive conditions.

As AI systems grow more powerful, they also become vulnerable. A new German research initiative aims to build the tools to detect AI manipulation.

Tempus AI's research at a key symposium shows its AI-driven edge, turning vast patient data into a powerful asset that could reshape oncology and investor outlooks.

After a financial tightrope walk, Actelis Networks is back in Nasdaq's good graces. But the real story is its mission to secure our future's IoT.

AskBio's gene therapies for Parkinson's and heart failure have received Japan's SAKIGAKE designation, promising a faster path to patients.

Accenture is training 30,000 pros on Anthropic's Claude AI, tackling the biggest barrier to enterprise AI: moving from costly experiments to real value.

Aviz Networks just launched a certified SONiC distribution, aiming to break down the barriers of complexity and support that have kept open networking on the sidelines.

Target RWE's strategic hire of NoviSci co-founder Alan Brookhart signals a major push to master regulatory-grade real-world evidence. What does this mean?

Groundbreaking lymphoma data and a strategic acquisition position Natera to dominate the liquid biopsy market, challenging old standards and creating new value.

Vancouver's SimplyAsk.ai and Mexican telecom giant Axtel partner to tackle AI's high failure rate, aiming to unlock a multi-billion dollar market.

Beyond the award, Pariveda's use of generative AI to modernize legacy systems reveals a powerful new playbook for enterprise transformation and value.

With its new 'Eagle Line' pilot facility online, QuantumScape takes a leap toward the EV future. We analyze the tech, the risks, and the competition.

A key safety milestone for Opus Genetics' OPGx-BEST1 gene therapy trial offers a glimmer of hope for thousands facing progressive vision loss from Best disease.

With validated Phase 1b data, ONL Therapeutics' novel drug aims to protect vision cells, not just slow disease, in a challenge to current GA therapies.